Beneficial effects found with combined usage of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors
1. Compared with using only using a GLP-1 receptor agonist or an SGLT-2 inhibitor, combination therapy with both drug classes was associated with a reduced risk of major adverse cardiac events (MACEs) and serious renal events. 2. The risk of serious renal events...